Recombinant human C1 esterase inhibitor vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 1.5 [0.06, 34.66]1 study · 29 participantsVery low